Drug intelligence / Profile preview

HEPTOMUCH-DS

Development stage: Unknown
Lead developer: Allgems Healthcare
Modality: Small Molecules
Administration: Oral

Overview

HEPTOMUCH-DS is a liver support supplement developed and marketed by Allgems Healthcare. It is positioned as a branded generic within the gastrointestinal and liver health segment. The DS suffix typically indicates a Double Strength formulation. It is intended for the management of liver disorders and to provide general hepatoprotection. While specific ingredients are not detailed in the provided pipeline, such supplements in this market often contain hepatoprotective agents like silymarin, L-ornithine L-aspartate, or various Ayurvedic herbal extracts.

Brand names: HEPTOMUCH-DS
Other names: HEPTOMUCH DS

Beyond the preview

Go deeper on HEPTOMUCH-DS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEPTOMUCH-DS.

Explore the full profile